Metabolic

Adipotide

Peptidomimetic · Pro-apoptotic sequence · Synthetic

FDA · PRECLINICAL ONLY

Half-life

~3 hours

Short

minsdays

Route

SubQ injection

Evidence

Preclinical only

Risk

Experimental

Overview

Known for

Experimental fat-loss peptide. Targets blood vessels that supply white adipose (fat) tissue, causing fat cell apoptosis (death). Very potent but carries significant kidney toxicity risk.

Mechanism

Peptidomimetic that targets PROHIBITIN on blood vessels feeding fat tissue, cutting blood supply → fat cell apoptosis. ⚠️ EXPERIMENTAL.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Active
Supply & nature
ExogenousExogenous
FDA category
Preclinical only

Evidence & standing

Evidence base
Preclinical only
Risk level
Experimental
Clinical phase
Pre-clinical
Best studies
4 references
  • Barnhart et al. (2011) Sci Transl Med 3(108). DOI: 10.1126/scitranslmed.3002621 — Targeted obesity therapy in primates
  • Showed renal toxicity in primate studies
  • NO HUMAN TRIALS COMPLETED
  • ⚠️ HIGH RISK — experimental compound

Dosage & protocol

Typical dose
0.5-1mg
Research range
0.5–1 mg/kg
Cycle
4 weeks on / 8 weeks off
Onset
10 days first effects
Full effect
21 days
Half-life
~2-4h
~2-4 hours (estimated)
Protocol

0.5-1mg/kg per week (highly experimental). Often cited at 0.1-0.5mg/day. Very limited human data.

Time to effects

EARLY: 1-2 weeks

FULL: 2-4 weeks

Effects are rapid due to the mechanism (cutting blood supply to fat cells). Visible fat reduction can occur within 2 weeks.

⚠️ However, kidney stress also occurs rapidly. Cycles are kept very short (2-4 weeks max) specifically because of toxicity concerns. Monitor kidney function closely.

Recommended vial
  • 2mg vials

Short cycles only (2-4 wks). 2mg at 0.1-0.5mg/day = 4-20 days ✓. 5mg vial likely won't be used in time.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Not Reversible
Side effects

⚠️ KIDNEY TOXICITY observed in primate studies: renal tubular degeneration, elevated BUN/creatinine. Dehydration.

Interactions

NSAIDs, nephrotoxic drugs (additive kidney damage risk). ACE inhibitors.

Handle with research caution

  • Do NOT combine with other nephrotoxic compounds
  • Caution combining with NSAIDs (compounded kidney stress)
  • ⚠️ High-risk compound — minimise polypharmacy

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
2–4 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.